A Robert1, Y Pointreau2, G Janoray3, É Bardet4, M Fesneau5, P Garaud6, S Chapet3, C Lafond2, O Dupuis2, G Calais3. 1. Department of Oncology Radiotherapy, pôle Henry-S-Kaplan, CHRU Bretonneau, 2, boulevard Tonnellé, 37044 Tours, France. Electronic address: rob.aurel@gmail.com. 2. Department of Oncology Radiotherapy, centre Jean-Bernard-clinique Victor-Hugo, 9, rue Beauverger, 72000 Le Mans, France. 3. Department of Oncology Radiotherapy, pôle Henry-S-Kaplan, CHRU Bretonneau, 2, boulevard Tonnellé, 37044 Tours, France. 4. Department of Oncology Radiotherapy, centre René-Gauducheau, institut de cancérologie de l'Ouest, boulevard Professeur-Jacques-Monod, 44805 Saint-Herblain, France. 5. Department of Oncology Radiotherapy, centre hospitalier régional d'Orléans, 14, avenue de l'Hôpital, 45100 Orléans, France. 6. Groupe oncologie radiothérapie tête et cou (GORTEC), association Gortec, Corad Chu Bretonneau, 37044 Tours cedex 1, France.
Abstract
PURPOSE: The main objective of this study was to evaluate the 5-year efficacy of exclusive laryngeal radiotherapy without node prophylactic irradiation for localized cancers of the vocal cords. PATIENTS AND METHODS: We retrospectively reviewed charts from 258 patients with T1-T2N0 glottic carcinoma irradiated from April 1987 to March 2015 in four France western centers, including pretreated patients. Toxicity was analyzed according to CTCAE v4.0 classification. RESULTS: The median follow-up was 50 months. The median age was 67 years with 87% men and 85.5% had T1 tumor. Five years overall survival was 77.5% (95% confidence interval [95% CI]: 71.4-83.5), 5 years local control was 86.8% (95% CI: 82.3-91.3), specific survival rate was 95% (95% CI: 92.2-97.9) and final laryngectomy-free survival was 87.5% (95% CI: 82.2-92.9). Most toxicities were grade 1 and 2. Grade 3 acute toxicity was 15.5% for the radiation laryngitis, 3.5% for radiodermatitis and 7.7% for dysphonia. Grade 3 chronic toxicity was 3.5% for dysphonia and there were two cases of tracheal stenosis treated by tracheotomy. CONCLUSION: Radiotherapy provides good results in local control of stage I and II vocal cords cancers as well as the toxicity level.
PURPOSE: The main objective of this study was to evaluate the 5-year efficacy of exclusive laryngeal radiotherapy without node prophylactic irradiation for localized cancers of the vocal cords. PATIENTS AND METHODS: We retrospectively reviewed charts from 258 patients with T1-T2N0 glottic carcinoma irradiated from April 1987 to March 2015 in four France western centers, including pretreated patients. Toxicity was analyzed according to CTCAE v4.0 classification. RESULTS: The median follow-up was 50 months. The median age was 67 years with 87% men and 85.5% had T1 tumor. Five years overall survival was 77.5% (95% confidence interval [95% CI]: 71.4-83.5), 5 years local control was 86.8% (95% CI: 82.3-91.3), specific survival rate was 95% (95% CI: 92.2-97.9) and final laryngectomy-free survival was 87.5% (95% CI: 82.2-92.9). Most toxicities were grade 1 and 2. Grade 3 acute toxicity was 15.5% for the radiation laryngitis, 3.5% for radiodermatitis and 7.7% for dysphonia. Grade 3 chronic toxicity was 3.5% for dysphonia and there were two cases of tracheal stenosis treated by tracheotomy. CONCLUSION: Radiotherapy provides good results in local control of stage I and II vocal cords cancers as well as the toxicity level.
Authors: Sebastian Strieth; Benjamin P Ernst; Ina Both; Daniel Hirth; Lara N Pfisterer; Julian Künzel; Katharina Eder Journal: Head Neck Date: 2019-01-31 Impact factor: 3.147